31.31

2.52% 0.77

Pre-market: 30.31 -1.00 -3.19%

Mbx Biosciences Inc (MBX)

Overview News Price History Discussions Forecast

Mbx Biosciences Inc stock is traded at $31.31, with a volume of 463.36K. It is up +2.52% in the last 24 hours and down -18.40% over the past month. MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.

Previous Close:

$30.54

Open:

$30.91

24h Volume:

463.36K

Relative Volume:

0.64

Market Cap:

$1.41B

Revenue:

Net Income/Loss:

$-47.20M

P/E Ratio:

-20.00

EPS:

-1.5653

Net Cash Flow:

$-43.65M

1W Performance:

-12.15%

1M Performance:

-18.40%

6M Performance:

+142.34%

1Y Performance:

+190.45%

1-Day Range:

$30.25

$32.45

1-Week Range:

$30.25

$35.70

52-Week Range:

$4.8069

$44.89

Mbx Biosciences Inc Stock (MBX) Company Profile

Name

Mbx Biosciences Inc

Sector

Healthcare (1106)

Industry

Biotechnology (621)

Phone

(317) 989-3100

Address

11711 N. MERIDIAN STREET, CARMEL

Employee

Twitter

Next Earnings Date

Latest SEC Filings

MBX's Discussions on Twitter

Compare MBX vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MBX Mbx Biosciences Inc	31.31	1.37B	0	-47.20M	-43.65M	-1.5653
VRTX Vertex Pharmaceuticals Inc	477.89	120.48B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	787.50	81.05B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	749.56	46.33B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	327.30	42.26B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	299.02	32.87B	5.36B	287.73M	924.18M	2.5229

Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-28-26	Initiated	Barclays	Overweight
Dec-04-25	Initiated	Goldman	Sell
Nov-04-25	Initiated	TD Cowen	Buy
Oct-15-25	Initiated	Truist	Buy
Aug-15-25	Resumed	Jefferies	Buy
Aug-05-25	Initiated	Mizuho	Outperform
Jul-16-25	Initiated	Oppenheimer	Outperform
Apr-10-25	Initiated	Citizens JMP	Mkt Outperform
Oct-08-24	Initiated	Guggenheim	Buy
Oct-08-24	Initiated	JP Morgan	Overweight
Oct-08-24	Initiated	Jefferies	Buy
Oct-08-24	Initiated	Stifel	Buy

View All

Mbx Biosciences Inc Stock (MBX) Latest News

Mar 04, 2026

Loss Report: Is MBX Biosciences Inc benefiting from interest rate changesTrend Reversal & Technical Buy Zone Confirmations - baoquankhu1.vn

Mar 04, 2026

MBX Biosciences annonce une offre d'actions après un doublement de l'action - TradingView

Mar 04, 2026

Mar 03, 2026

MBX SEC FilingsMBX Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 03, 2026

Mar 02, 2026

MBX: Phase III and obesity data milestones, robust pipeline, and strong cash position drive outlook - TradingView

Mar 02, 2026

MBX: Clinically validated platform and robust pipeline drive multiple catalysts and strong financial outlook - TradingView

Mar 02, 2026

Mar 01, 2026

Tech Rally: Is MBX Biosciences Inc benefiting from interest rate changesQuarterly Portfolio Report & High Conviction Buy Zone Alerts - baoquankhu1.vn

Mar 01, 2026

MBX Biosciences, Inc. (NASDAQ:MBX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Mar 01, 2026

Feb 28, 2026

MBX Biosciences Calls 2026 “Pivotal” With Phase 3 Plans, Obesity Program, and $460M Cash Runway - Yahoo Finance

Feb 28, 2026

Feb 27, 2026